CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
LY3016859 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04476108
NCT04476108Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company·interventional·Posted Jul 17, 2020·Updated Nov 14, 2023

In Brief

A Phase 2 clinical trial evaluating LY3016859 and Placebo for Diabetic Peripheral Neuropathic Pain. Completed, enrolled 125 participants across 36 sites in 2 countries.

Detailed Summary

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathic Pain
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 17, 2020
Enrollment StartJul 15, 2020
Primary CompletionJul 8, 2021
Study CompletionNov 11, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.0 years ago

Interventions

LY3016859drug

Administered IV

Placebodrug

Administered IV